The Effect of Fat Emulsion Intralipid Infusion on Reproductive Outcome for Women with Unexplained First Trimester Habitual Abortion
Journal of Advances in Medicine and Medical Research,
Objectives: To study the effect of the use of intralipid in management of women suffering from unexplained first trimester habitual abortion.
Methods: The study was a prospective cohort study, which conducted in Tanta university Hospital; Egypt. It included 93 women with history of two or more unexplained recurrent abortion in the first trimester. They were divided into three groups: group Ι received only intralipid, group II received low molecular weight heparin (LMWH) and low dose aspirin, and group III served as controls and received only saline as placebo. The patients were followed up until continuation of pregnancy into the second trimester. Occurrence of complication and pregnancy outcomes were evaluated.
Results: Ninety three women were included. After treatment, more pregnancy continued into the second trimester, more live births and less numbers of abortions in group A and B in comparison with group C (p=0.008, 0.008 and 0.035) respectively. Maternal and neonatal outcomes were comparable in all studied regimens.
Conclusions: Management of women with unexplained first trimester habitual abortion (before 14 weeks) with intralipid or LMWH with small dose of aspirin may increase the proportion of pregnancy continued into the second trimester, more live births and less numbers of abortions. However, LMWH is more superior to the intralipid but with more side effect.
- Intralipid infusion
- low molecular weight heparin
- unexplained first trimester habitual abortion.
How to Cite
Wang NF, Kolte AM, Larsen EC, Nielsen HS, Christiansen OB. Immunologic abnormalities, treatments, and recurrent pregnancy loss: What is real and what is not? Clinical obstetrics and gynecology. 2016;59(3):509-523.
Zhang L, Yang Y, Zhang R, Luo L, Tan J, Zhou L, et al. Comparison of the etiological constitution of two and three or more recurrent miscarriage. Zhonghua fu Chan ke za zhi. 2018;53(12):855-859.
Li X, Zhao J, Liu X. Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome. Beijing da xue xue bao Yi xue ban= Journal of Peking University Health Sciences. 2018;50(6):956-961.
Qian J, Zhang N, Lin J, Wang C, Pan X, Chen L, et al. Distinct pattern of Th17/Treg cells in pregnant women with a history of unexplained recurrent spontaneous abortion. Bioscience trends. 2018:78(07):677-683.
Zhao X, Jiang Y, Wang L, Li Z, Li Q, Feng X. Advances in understanding the immune imbalance between T-lymphocyte subsets and NK cells in recurrent spontaneous abortion. Geburtshilfe und Frauenheilkunde. 2018;78(07):677-683.
Kamoi M, Fukui A, Kwak‐Kim J, Fuchinoue K, Funamizu A, Chiba H, et al. NK 22 Cells in the Uterine Mid‐Secretory Endometrium and Peripheral Blood of Women with Recurrent Pregnancy Loss and Unexplained Infertility. American Journal of Reproductive Immunology. 2015;73(6):557-567.
Bruno V, Svensson-Arvelund J, Rubér M, Berg G, Piccione E, Jenmalm MC, et al. Effects of low molecular weight heparin on the polarization and cytokine profile of macrophages and T helper cells in vitro. Scientific Reports. 2018;8(1):1-9.
Dakhly DM, Bayoumi YA, Sharkawy M, Allah SHG, Hassan MA, Gouda HM, et al. Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells. International Journal of Gynecology & Obstetrics. 2016;135(3):324-327.
Lédée N, Vasseur C, Petitbarat M, Chevrier L, Vezmar K, Dray G, et al. Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation. Journal of Reproductive Immunology. 2018;130:18-22.
Martini AE, Jasulaitis S, Fogg LF, Uhler ML, Hirshfeld-Cytron JE. Evaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure. Journal of Human Reproductive Sciences. 2018;11(3):261- 270.
Kang X, Wang T, He L, Xu H, Liu Z, Zhao A. Effect of low‐dose aspirin on midluteal phase uterine artery blood flow in patients with recurrent pregnancy loss. Journal of Ultrasound in Medicine. 2016;35(12):2583-7587.
Shaaban OM, Abbas AM, Zahran KM, Fathalla MM, Anan MA, Salman SA. Low-molecular-weight heparin for the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies: a randomized controlled trial. Clinical and Applied Thrombosis/ Hemostasis. 2017;23(6):567-572.
Meng L, Lin J, Chen L, Wang Z, Liu M, Liu Y, et al. Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion. Archives of Gynecology and Obstetrics. 2016;294(1):29-39.
Mekinian A, Cohen J, Alijotas‐Reig J, Carbillon L, Nicaise‐Roland P, Kayem G, et al. Unexplained recurrent miscarriage and recurrent implantation failure: Is there a place for immunomodulation? American Journal of Reproductive Immunology. 2016;76(1):8-28.
Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? American Journal of Reproductive Immunology. 2012;67(4):296-304.
Achilli C, Duran-Retamal M, Saab W, Serhal P, Seshadri S. The role of immunotherapy in in vitro fertilization and recurrent pregnancy loss: a systematic review and meta-analysis. Fertility and sterility. 2018;110(6):1089-1100.
Singh N, Davis AA, Kumar S, Kriplani A. The effect of administration of intravenous intralipid on pregnancy outcomes in women with implantation failure after IVF/ICSI with non-donor oocytes: A randomised controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019;240:45-51.
Abstract View: 105 times
PDF Download: 35 times